SCHEMBL15869701

SCHEMBL15869701

Cc1ccc(Oc2ccccc2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.54
DRD4 P21917 1/20 0.54
DRD3 P35462 1/20 0.54
LTA4H P09960 4/20 0.48
TSHR P16473 1/20 0.48
HTR2A P28223 1/20 0.45
SLC6A4 P31645 1/20 0.45
KCNH2 Q12809 1/20 0.45
AR P10275 1/20 0.45
KMO O15229 1/20 0.45
POLB P06746 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 1/20 0.44
MAOB P27338 1/20 0.44
NR1H2 P55055 1/20 0.43
BAX Q07812 1/20 0.43
MAOA P21397 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14396803 0.89 HTR2A (0.51) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL8736417 0.86 TEAD4 (0.48) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL675954 0.86 HTR2A (0.54) DRD2DRD4DRD3LTA4HHTR2A
SCHEMBL15869698 0.85 SLC6A4 (0.50) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL11543548 0.84 ALDH1A1 (0.54) LTA4HTSHRHTR2ASLC6A4KCNH2
SCHEMBL14649910 0.83 HSP90AA1 (0.57) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL25962954 0.83 SMN1; SMN2 (0.56) DRD2DRD4DRD3LTA4HHTR2A
SCHEMBL4371877 0.82 NPC1 (0.46) HTR2ASLC6A4KCNH2ARCYP3A4
SCHEMBL12260919 0.82 HTR2A (0.44) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL10007534 0.81 LTA4H (0.55) DRD2DRD4DRD3LTA4HTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170182053-A1 TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF ARQULE, INC. 2017-06-29 US disclosed
US-9630968-B1 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof ARQULE, INC. (US) 2017-04-25 US disclosed
US-9556150-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. (US) 2017-01-31 US disclosed
US-20160311801-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE CHUGAI PHARMACEUTICAL CO. (JP) 2016-10-27 US disclosed
US-9056862-B2 Thioxothiazolidine derivative having Ras function inhibitory effect NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2015-06-16 US disclosed
US-9056862-B2 Thioxothiazolidine derivative having Ras function inhibitory effect NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2015-06-16 US disclosed
US-20140194412-A1 THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT KNC LABORATORIES CO., LTD. (JP) 2014-07-10 US disclosed
US-20140194412-A1 THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT KNC LABORATORIES CO., LTD. (JP) 2014-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170182053-A1 TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF BTK, SYK, LCK DRD2 4598/4885DRD4 4307/4885DRD3 3995/4885
US-20160311801-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN DRD2 4426/4885DRD4 4805/4885DRD3 4505/4885
US-20140194412-A1 THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT KRAS, NRAS, RASSF5 DRD2 4040/4885DRD4 2977/4885DRD3 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.